Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Shares Are Tumbling Today

By Keith Speights – Jun 3, 2020 at 11:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two factors appear to be behind Sorrento's stock decline.

What happened

Shares of Sorrento Therapeutics (SRNE -4.32%) had fallen 10.6% lower as of 11:12 a.m. EDT on Wednesday. The company hadn't reported any news, but a couple of factors may have been behind the sell-off.

First, the stocks of most drugmakers working on COVID-19 vaccines fell after Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), stated in an interview with JAMA editor Howard Bauchner that COVID-19 vaccines likely won't provide a long period of immunity.

Second, Sorrento has been hit with a deluge of lawsuits over the last few days. These lawsuits allege that the company made misleading statements about its clinical programs, with some of the legal filings specifically referring to public statements about Sorrento's COVID-19 program.

Man with hands on his head with a declining stock chart in the background

Image source: Getty Images.

So what

Fauci is widely viewed as one of the leading authorities on COVID-19. When he expresses concern about how well vaccines will work against the novel coronavirus, it's worth taking note. However, Fauci also stated that he's "cautiously optimistic" that there will be a safe and effective COVID-19 vaccine. 

Most of the surge in investors' interest in Sorrento has stemmed from its COVID-19 efforts. Until the drugmaker has solid results to report from clinical studies of its COVID-19 programs, the biotech stock is likely to be highly volatile and to fall on stories like the recent interview with Fauci.

What about those lawsuits? They're not unusual. Drugmakers get sued all the time. It's too soon to know how litigation will play out.

Now what

The most important thing to watch with Sorrento right now is its clinical progress in COVID-19 and in other areas. So far, the company's main achievements on the COVID-19 front have been conducting preclinical tests and forging partnerships with third parties. These are good first steps, but investors will need to see results to have confidence in Sorrento.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.55 (-4.32%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
328%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.